These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1232 related items for PubMed ID: 25381876

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group.
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [Abstract] [Full Text] [Related]

  • 5. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM, Burgess L, Korányi L, Hruba V, Hamer-Maansson JE, de Bruin TW.
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
    Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E, Study 05 Group.
    Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
    [Abstract] [Full Text] [Related]

  • 9. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 10. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S, Catrinoiu D, Celiński A, Ekholm E, Cook W, Hirshberg B, Chen H, Iqbal N, Hansen L.
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [Abstract] [Full Text] [Related]

  • 11. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L, Ma J, Li H, Mansfield TA, T'joen CL, Iqbal N, Ptaszynska A, List JF.
    Clin Ther; 2014 Jan 01; 36(1):84-100.e9. PubMed ID: 24378206
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ.
    Diabetes Obes Metab; 2013 Dec 01; 15(12):1154-60. PubMed ID: 23906374
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
    Mathieu C, Herrera Marmolejo M, González González JG, Hansen L, Chen H, Johnsson E, Garcia-Sanchez R, Iqbal N.
    Diabetes Obes Metab; 2016 Nov 01; 18(11):1134-1137. PubMed ID: 27385192
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Jeong IK, Choi KM, Han KA, Kim KA, Kim IJ, Han SJ, Lee WY, Yoo SJ.
    Diabetes Obes Metab; 2024 Nov 01; 26(11):5065-5077. PubMed ID: 39223856
    [Abstract] [Full Text] [Related]

  • 15. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, Chin A, Hansen L.
    Diabetes Obes Metab; 2016 Nov 01; 18(11):1128-1133. PubMed ID: 27403645
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
    Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S.
    Diabetes Obes Metab; 2013 May 01; 15(5):432-40. PubMed ID: 23194084
    [Abstract] [Full Text] [Related]

  • 17. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.
    Dtsch Med Wochenschr; 2013 Apr 01; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [Abstract] [Full Text] [Related]

  • 18. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ.
    Diabetes Obes Metab; 2013 Aug 01; 15(8):721-8. PubMed ID: 23398530
    [Abstract] [Full Text] [Related]

  • 19. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
    Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF.
    BMC Med; 2013 Feb 20; 11():43. PubMed ID: 23425012
    [Abstract] [Full Text] [Related]

  • 20. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.
    Diabetes Obes Metab; 2011 Oct 20; 13(10):928-38. PubMed ID: 21672123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.